
Sarcomas
Latest News
Latest Videos

More News

The addition of ifosfamide to doxorubicin in the treatment of advanced soft tissue sarcomas delayed disease progression but did not improve survival.

Dr. George Demetri, from the Dana-Farber Cancer Institute, Describes the Mechanism of Action of Regorafenib in Gastrointestinal Stromal Tumors.

Dr. George Demetri, from Dana-Farber Cancer Institute, Explains the Side Effects Associated With Regorafenib.

The FDA has approved pazopanib for the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy.

A combination of immunotherapy and fractionated external-beam radiation therapy provided tumor-specific immune responses in patients with soft-tissue sarcoma.

ODAC has recommended the approval of pazopanib but ruled against the agent ridaforolimus to treat sarcoma.

Patients with anthracycline-treated sarcomas had a 3-fold improvement in PFS with antiangiogenic agent pazopanib versus placebo.

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST

Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses the Progress of gastrointestinal stromal tumors (GIST) Treatments

The FDA has awarded a $600,000 grant for a phase I clinical trial of a genetically reprogrammed herpes simplex virus in young cancer patients with relapsed non-central nervous system (CNS) solid tumors such as sarcomas and neuroblastomas.

Useful Online Resources and Clinical Trials for Childhood-Tumors














































































